Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Creative Medical Technology Holdings (CELZ) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Creative Medical Technology Holdings (CELZ) over the last 14 years, with Q3 2025 value amounting to $37100.0.

  • Creative Medical Technology Holdings' Non Operating Income fell 4664.86% to $37100.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $121358.0, marking a year-over-year decrease of 6110.13%. This contributed to the annual value of $250380.0 for FY2024, which is 2493.66% down from last year.
  • Latest data reveals that Creative Medical Technology Holdings reported Non Operating Income of $37100.0 as of Q3 2025, which was down 4664.86% from $30217.0 recorded in Q2 2025.
  • Creative Medical Technology Holdings' 5-year Non Operating Income high stood at $28.1 million for Q1 2021, and its period low was -$2.4 million during Q4 2021.
  • Moreover, its 5-year median value for Non Operating Income was $61147.0 (2023), whereas its average is $1.4 million.
  • Within the past 5 years, the most significant YoY rise in Creative Medical Technology Holdings' Non Operating Income was 59012.51% (2021), while the steepest drop was 25850.07% (2021).
  • Creative Medical Technology Holdings' Non Operating Income (Quarter) stood at -$2.4 million in 2021, then surged by 102.59% to $62245.0 in 2022, then surged by 49.84% to $93265.0 in 2023, then tumbled by 66.05% to $31660.0 in 2024, then rose by 17.18% to $37100.0 in 2025.
  • Its Non Operating Income was $37100.0 in Q3 2025, compared to $30217.0 in Q2 2025 and $22381.0 in Q1 2025.